Example: Heart Attack

Clinical Trials on Bronchial Neoplasms

Total 4889 results

    • NCT03516214
      Recruiting
      EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
      Conditions: Bronchial Neoplasms
    • NCT03745859
      Recruiting
      Evaluation of a New Open Source Virtual Bronchoscope Navigation System
      Conditions: Bronchial Neoplasms
    • NCT02745002
      Recruiting
      Navigated EBUS and Functional Imaging in Lung Cancer
      Conditions: Bronchial Neoplasms
    • NCT02493023
      Completed
      Automatic CT-to-patient Registration During Navigated Bronchoscopy and EBUS
      Conditions: Bronchial Neoplasms
    • NCT04413292
      Completed
      Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases
      Conditions: Bronchial Neoplasm Benign
    • NCT01261585
      Completed
      Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT
      Conditions: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung
    • NCT02050724
      Terminated
      ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT
      Conditions: Solitary Pulmonary Nodule; Bronchial Neoplasms
    • NCT01575314
      Completed
      Cost-consequence Analysis of Parenchymal Stapling Device Versus Hand-sewing for Pulmonary Lobectomy in Lung Disease
      Conditions: Malignant Neoplasm of Bronchus or Lung, Unspecified
    • NCT01841060
      Completed
      Assessment of the Effectiveness of Local Ablathermy Radio Frequency Bronchial Tumors Primitive
      Conditions: Malignant Non-small Cell Neoplasm of Lung Stage Ia
    • NCT02804100
      Unknown status
      Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
      Conditions: Carcinoma, Non-Small-Cell Lung; Bronchial Neoplasms; Carcinoma, Bronchogenic; Lung Diseases; Lung Neoplasms
    • NCT02264210
      Recruiting
      Icotinib for Completed Resected IB NSCLC With EGFR Mutation
      Conditions: Lung Neoplasms; Squamous Cell Lung Cancer; Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Large Cell Lung Cancer; Bronchial Neoplasms; Stage IB Non-small Cell Lung Cancer
    • NCT01802203
      Active, not recruiting
      trūFreeze® Spray Cryotherapy Patient Registry
      Conditions: Barrett Esophagus; Esophageal Dysplasia; Esophageal Neoplasm; Esophageal Stenosis; Bronchial Neoplasm; Stenosis of Bronchus or Trachea
    • NCT03892408
      Unknown status
      High-flow Nasal Oxygen During Rigid Bronchoscopy Under General Anesthesia: a Randomized Controlled Trial
      Conditions: Foreign Bodies; Tumor; Stenosis Trachea; Bronchus Tumour
    • NCT03402048
      Recruiting
      The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial
      Conditions: Stage IV, NSCLC; Lung Neoplasms; Bronchial Neoplasms; Carcinoma, Bronchogenic; Lung Diseases; Neoplasms; Respiratory Tract Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms
    • NCT02897778
      Completed
      Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
      Conditions: Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Digestive System Neoplasms; Endocrine Gland Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Diseases; Breast Neoplasms; Breast Diseases; Renal Neoplasm; Solid Tumors
    • NCT03037385
      Recruiting
      Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
      Conditions: RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer; RET-altered Colon Cancer; RET-altered Solid Tumors; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Thyroid Diseases; Thyroid Neoplasm; Thyroid Cancer, Papillary; Carcinoma, Neuroendocrine; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Endocrine System Diseases; Endocrine Gland Neoplasm; Head and Neck Neoplasms; Adenocarcinoma, Papillary; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Colonic Neoplasms; Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Disease; Colonic Diseases; Intestinal Disease
    • NCT02909452
      Unknown status
      Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
      Conditions: Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Digestive System Neoplasms; Endocrine Gland Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Diseases; Breast Diseases; Renal Neoplasm; Solid Tumors
    • NCT04697446
      Enrolling by invitation
      External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
      Conditions: RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Metastatic Non Small Cell Lung Cancer
    • NCT04222972
      Recruiting
      AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC
      Conditions: RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue
    • NCT02378337
      Completed
      Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
      Conditions: Malignant Neoplasm of Breast; Hodgkin Disease; Non-Hodgkin Lymphoma, Follicular (Nodular); Malignant Neoplasm of Bronchus and Lung; Malignant Neoplasm of Colon; Secondary Neoplasm Malignant and Unspecified Lymph Nodes; Malignant Melanoma of the Skin; Malignant Neoplasm of Small Intestine
    • NCT02288026
      Unknown status
      Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
      Conditions: Stage IA Non-small Cell Lung Cancer; Adenocarcinoma of the Lung; Squamous Cell Lung Cancer
    • NCT04133337
      Not yet recruiting
      Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
      Conditions: Lung Diseases; Neoplasms; Respiratory Tract Diseases; Thoracic Neoplasms; Non-small-cell Lung Cancer
    • NCT02826161
      Terminated
      A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
      Conditions: Carcinoma, Non-Small-Cell Lung
    • NCT02904954
      Active, not recruiting
      Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer
      Conditions: Carcinoma, Non-Small-Cell Lung
    • NCT04512430
      Recruiting
      Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
      Conditions: Non-Small Cell Lung Cancer, Positive for Epidermal Growth Factor Receptor Expression
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations